In Vitro Studies Indicate that Miquelianin (Quercetin 3-O-ß-D-Glucuronopyranoside) is Able to Reach the CNS from the Small Intestine

 

 Buy Article Permissions and Reprints

Abstract

Miquelianin (quercetin 3-O-ß-D-glucuronopyranoside) is one of the flavonoids of St. John’s wort (Hypericum perforatum L.) whose antidepressant activity has been shown by the forced swimming test, an in vivo pharmacological model with rats. However, nothing is known about its ability to reach the CNS after oral administration. We examined the pathway of miquelianin from the small intestine to the central nervous system using three in vitro membrane barrier cell systems. In the Caco-2 cell line, miquelianin showed a higher uptake (1.93 ± 0.9 pmol × min^-1 × cm^-2) than hyperoside (quercetin 3-O-ß-D-galactopyranoside; 0.55 ± 0.18 pmol × min^-1 × cm^-2) and quercitrin (quercetin 3-O-α-L-rhamnopyranoside; 0.22 ± 0.08 pmol × min^-1 × cm^-2). The permeability coefficient of miquelianin (P _c = 0.4 ± 0.19 × 10 ^{- 6} cm/sec) was in the range of orally available drugs assuming sufficient absorption from the small intestine. Uptake and permeability of the examined compounds was increased by the MRP-2 inhibitor MK-571 indicating a backwards transport by this membrane protein. Porcine cell cultures of brain capillary endothelial cells were used as a model of the blood-brain barrier (bbb) and epithelial cells of the plexus chorioidei as a model of the blood-CSF barrier (bcb). Results indicate no active transport in one direction. Although moderate, the permeability coefficients (bbb: P _c = 1.34 ± 0.05 × 10 ^{- 6} cm/sec; bcb: P _c = 2.0 ± 0.33 × 10 ^{- 6} cm/sec) indicate the ability of miquelianin to cross both barriers to finally reach the CNS.

References

• 1 Schulz V. Klinische Studien mit Hypericum-Extrakten bei Patienten mit Depressionen.  Z Phytother. 2002;  23 11-5
  PubMedGoogle Scholar
• 2 Nahrstedt A. Antidepressant constituents of Hypericum perforatum . In: Chrubasik S, Roufogalis BD, editors Herbal medicinal products for the treatment of pain.  Lismore NSW; Southern Cross University Press 2000: pp. 144-53
  Google Scholar
• 3 Butterweck V, Christoffel V, Nahrstedt A, Petereit F, Spengler B, Winterhoff H. Step by step removal of hyperforin and hypericin: Activity profile of different Hypericum preparations in behavioural models.  Life Sciences. 2003;  73 627-39
  PubMedGoogle Scholar
• 4 Butterweck V, Juergenliemk G, Nahrstedt A, Winterhoff H. Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test.  Planta Med. 1999;  66 3-6
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Gee J M, Dupont M S, Day A J, Plumb G W, Williamson G, Johnson I T. Intestinal transport of quercetin glycosides in rats involves both deglycosylation and interaction with the hexose transport pathway.  J Nutr. 2000;  130 2765-71
  PubMedGoogle Scholar
• 6 Graefe E U, Wittig J, Mueller S, Riethling A K, Uehleke B, Drewelow B, Pforte H, Jacobasch G, Derendorf H, Veit M. Pharmacokinetics and bioavailability of quercetin glycosides in humans.  Herbal Med. 2001;  41 492-9
  CrossrefPubMedGoogle Scholar
• 7 Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells.  Biochem Biophys Res Commun. 1991;  175 880-5
  CrossrefPubMedGoogle Scholar
• 8 Franke H, Galla H J, Beuckmann C T. Primary cultures of brain microvessel endothelial cells: a valid and flexible model to study drug transport through the blood-brain barrier in vitro .  Brain Res Prot. 2000;  5 248-56
  CrossrefPubMedGoogle Scholar
• 9 Gath U, Hakvoort A, Wegener J, Decker S, Galla H J. Porcine choroid plexus cells in culture: expression of polarized phenotype, maintenance of barrier properties and apical secretion of CSF-components.  Europ J Cell Biol. 1997;  74 68-78
  PubMedGoogle Scholar
• 10 Juergenliemk G, Nahrstedt A. Phenolic compounds from Hypericum perforatum L.  Planta Med. 2002;  68 88-91
  Article in Thieme ConnectPubMedGoogle Scholar
• 11 Boje K. Phytochemische und biopharmazeutische Untersuchungen an Harpagophytum procumbens DC. PhD Thesis 2002 Münster, Germany;
  Google Scholar
• 12 Tewes B, Galla H J. Lipid polarity in brain capillary endothelial cells.  Endothelium. 2001;  8 207-20
  PubMedGoogle Scholar
• 13 Wegener J, Hakvoort A, Galla H J. Barrier function of porcine choroid plexus epithelial cells is modulated by cAMP-dependent pathways in vitro .  Brain Res. 2000;  853 115-24
  CrossrefPubMedGoogle Scholar
• 14 Artursson P, Karlsson J, Ocklind G, Schipper N. Studying transport process in absortive epithelia. In: Shaw AJ Epithelia cell culture - a practical approach.  RL Press 1996: pp. 111-33
  Google Scholar
• 15 Walgren R A, Lin J T, Kinne R KH, Walle T. Cellular uptake of dietary flavonoid quercetin-4′-ß-glucoside by sodium-dependent glucose transporter SGLT1.  J Pharmacol Exp Ther. 2000;  294 837-43
  PubMedGoogle Scholar
• 16 Walgren R A, Karnaky K J, Lindenmayer G E, Walle T. Efflux of dietary flavonoid quercetin-4′-ß-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2.  J Pharmacol Exp Ther. 2000;  294 830-6
  PubMedGoogle Scholar
• 17 Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - fact or myth.  Pharm Res. 1997;  14 763-6
  CrossrefPubMedGoogle Scholar
• 18 Tantishaiyakul V. Prediction of Caco-2 cell permeability using partial least squares multivariate analysis.  Pharmazie. 2001;  56 407-11
  PubMedGoogle Scholar
• 19 Walgren R A, Walle U K, Walle T. Transport of quercetin and its glucosides across human intestinal epithelial Caco-2 cells.  Biochem Pharmacol. 1998;  55 1721-7
  CrossrefPubMedGoogle Scholar
• 20 Engelbertz C, Korte D, Nitz T, Franke H, Haselbach M, Wegener J, Galla H J. The development of in vitro models for the blood brain and blood-CSF barriers. In: Begley DJ, Bradbury MW, Kreuter, J. editors The Blood-Brain Barrier and Drug Delivery to the CNS.  New York, Basel; Marcel Dekker, Inc 2000: pp. 33-63
  Google Scholar
• 21 Lohmann C, Huewel S, Galla H J. Predicting blood-brain barrier permeability of drugs: Evaluation of different in vitro assays.  J Drug Targ. 2002;  10 263-76
  PubMedGoogle Scholar
• 22 Haselbach M. Die Blut-Liquor-Schranke in vitro: Charakterisierung von Barrierefunktion und Transportvorgängen. PhD Thesis 2000 Münster, Germany;
  Google Scholar

Dr. Guido Juergenliemk

Institute of Pharmaceutical Biology and Phytochemistry

Westf. Wilhelms-University

Hittorfstr. 56

49149 Muenster

Germany

Phone: +49-251-833-3376

Fax: +49-251-833-8341

Email: jurgenl@uni-muenster.de